Activity
  • Leverage Life Sciences Software to Reduce Time to Market

    The days of maintaining paper records across the life sciences development and production pipeline are gone. Today’s regulatory requirements, not to mention the complexity of new treatments, requires organization that can only be provided electronically. However, while many life sciences teams have moved to electronic records software , many teams are still inadvertently creating data silos—both horizontally across business…
  • Module Type Package Unlocks the Flexibility Driving Pharma Innovation

    There can be little question that Industry 4.0 technologies are reshaping the way life sciences companies operate. In the wake of the rapid development of vaccines during the COVID-19 pandemic , more facilities than ever are being “born digital.” Some of these born-digital facilities are the result of new organizations with entirely digital strategies, and others are biopharmaceutical organizations that have been around…
  • Let your Personnel Lead you to the Adaptive Plant

    On Monday at the Emerson Exchange Users’ Conference , Emerson’s Michalle Adkins and AbbVie’s Jeff Ziolkowski moderated a panel with Fujifilm’s Soren Skerris , Takeda’s Dr. Nina Schwalb , Eli Lilly’s James Weber , and Emerson’s Christian Berg . The experts shared the strategies they have employed and the lessons they’ve learned on their journey across the BioPhorum Digital Plant Maturity Model toward creating adaptive…
  • Reduce Waste & Increase Efficiency in Clean-in-Place Processes

    While the idea of adding costs to a food and beverage or pharmaceutical industry process like Clean-in-Place/Steam-in-Place (CIP/SIP) has not traditionally been an easy decision, in today’s industrial environment that has changed. With the retirement of experts, the lack of availability of workers, the increase in materials costs and narrowness of margins, the principal way for food and beverage and pharma companies to…
  • Software Simplifies Technology Transfer

    The life sciences marketplace is changing faster than nearly any other industry. Gone are the days when companies focus on a single treatment to drive their entire business. Today’s life sciences manufacturers are challenged to bring new treatments to the marketplace as quickly as possible—a trend that was magnified during the COVID-19 pandemic . As a result, innovation is key today. And innovation requires technologies…
  • Manufacturing Solutions in Personalized Healthcare

    In our Part 1 post, Manufacturing Challenges in Personalized Healthcare , Emerson’s Christian Berg explored the challenges biopharmaceutical manufacturers face in advancing personalized healthcare. In this final part, he describes some solutions and technologies which facilitate the pursuit of the adaptive plant, as defined by the BioPhorum Digital Plant Maturity Model , required to meet these challenges. Christian…
  • Manufacturing Challenges in Personalized Healthcare

    When we hear the phrase “personalized healthcare,” many of us think about the medicines and therapeutics focused on our specific needs that deliver treatments to dramatically improve or restore our health and extend our lives. In a Pharma Focus Asia webinar, Pursuing the Adaptive Plant to Enable Personalized Healthcare , Emerson’s Christian Berg provides a broader perspective of personalized healthcare and its challenges…
  • BioPhorum’s Roadmap for Speed to Market with In-Line Monitoring and Real-Time Release

    Traditional manufacturing practices have served the biopharmaceutical industry well for years, but times are changing and a need for speed to market in life sciences while reducing manufacturing costs is putting a focus on enabling real-time release (RTR). Technologies such as advanced process control (APC), predictive analytics, in-line monitoring (ILM), and real-time release testing (RTRT) are critical to the new strategies…
  • BioPhorum Cell and Gene Therapy Personas and User Stories

    Earlier I featured two recent BioPhorum publications in these posts: BioPhorum MES of the Future BioPhorum Cell and Gene Therapy Actors and Process Maps Today, I’ll highlight the third and final publication, CGT Personas and User Stories , from this release of publications. As with the other two, Emerson’s Sean Buckley was one of the primary authors, along with others from Cytiva, Dassault Systems, Novartis…
  • Shorten the Equipment Validation Process to Bring Projects Online Faster

    One of the key stages delaying and increasing costs in life sciences projects is equipment validation. In fact, it is one of the elements of project completion that project teams are most eager to compress because the value of every incremental improvement is so great. As Michalle Adkins explains in her recent article in Pharma Manufacturing , “Ultimately, the total cost and time of the full validation process can be…
  • BioPhorum Cell and Gene Therapy Actors and Process Maps

    A few weeks ago I highlighted one of the three new BioPhorum publications, MES of the Future Manifesto . Today, I’ll highlight a second one, CGT [cell & gene therapy] Actors and Process Maps . Emerson’s Sean Buckley was one of the authors along with co-authors from Roche, Takeda, and BioPhorum. Contributions were made during this Cell and Gene Therapy workstream from numerous biopharmaceutical manufacturers and software…
  • Is the Biotech Industry Growing?

    In the biotech realm, many struggle to find experienced and technically savvy providers who can provide unique solutions in control automation. As trends accelerate in the biopharmaceutical industry, manufacturers are looking for new and improved approaches to address industry challenges. What role does Emerson play? Explore Emerson’s Single-Use Technologies to learn how Emerson offers control systems that save…
  • BioPhorum MES of the Future

    We’ve highlighted the work of Emerson experts in the Biophorum Operations Group in several posts . Its mission: …is to create environments where the global biopharmaceutical industry can collaborate and accelerate its rate of progress, for the benefit of all. Emerson’s Sean Buckley alerted me to three recently published documents that he helped develop. These documents include: MES of the Future Manifesto CGT…
  • Hygienic Pressure Measurement for Pharmaceutical and Bioprocess Applications

    The tolerance for pharmaceutical and bioprocess manufacturing variations is relatively small to meet the quality requirements of finished medicines and therapeutics. In a Process Instrumentation article, How to ensure reliable pressure transmitter measurement in pharmaceutical applications , Emerson’s Brandon Haschke shares how “Advanced hygienic pressure transmitters can reduce downtime and operating costs thanks to…
  • Overcoming Pharmaceutical and Biotech Manufacturing Challenges

    Recently, the Pharma Manufacturing World Summit was held in Boston. The focus of the conference is to improve: … cost performance while maintaining quality and compliance in the midst of rapidly changing supply chain models among internal and external manufacturing… Emerson’s Christian Berg presented Are We There Yet? Tackling Manufacturing Challenges with the Digital Plant. Christian opened with the idea that tackling…
  • Faster Tech Transfer Unlocks Speed to Market

    The rapid development of the COVID-19 vaccine has created a dramatic shift in the way the public and life sciences organizations view the manufacturing of pharmaceuticals. In a recent Q&A with Pharma Manufacturing , Nathan Pettus , president of Emerson’s process systems and solutions business, shared how a move toward more flexibility and modularity in the industry is cutting tech transfer times to drive improved speed…
  • Adaptable Landscape Components Facilitate Digital Transformation

    The BioPhorum Operations Group (BPOG) established a digital plant maturity model (DPMM) for biopharmaceutical manufacturing to define stages of factory evolution “from simple paper-based plants through to the fully automated and integrated ‘adaptive plant’ of the future.” The model gives organizations a common tool for industry comparison and measurement of progress. It also provides a platform to facilitate collaboration…
  • Remote Monitoring Lays the Foundation for Lights-Out Manufacturing

    It isn’t news that the global pandemic upended the way we operate our plants. When social distancing trapped our most valuable personnel outside the facilities we rely on, it suddenly meant finding new ways to get critical work done. But the reality is, those changes would have been coming—albeit less quickly—even without the influence of COVID. Retirements and shortages of experienced workers have been thinning out…
  • Improve Speed to Market with Closed-Loop Process Control using Spectral PAT

    We have witnessed an incredible change the last few years in how life sciences manufacturers deliver treatments . Today’s focus is on fast results, and that means products patients rely on cannot sit on shelves for weeks or months waiting on quality validation. In a recent article in Pharmaceutical Processing World , Emerson’s Bob Lenich and Bruce Greenwald explored a strategy plants are using to digitally transform…
  • Ultrasonic Welding Helps Ramp Up COVID Test Production

    Demand for COVID test kits remain high and challenge manufacturers to maximize their production levels. In a Plastic News article (registration required), Automation suppliers help meet demand for COVID-19 testing kits , Emerson’s Vernon Murray , president of Branson assembly and welding technologies, highlighted the importance of welding technology in driving production efficiency. The article opens noting the production…
  • Regulatory Requirements for Medical Devices Webinar

    There is a new requirement for medical device companies selling into the European market, called the Medical Device Regulation, or MDR. This new regulation places a focus on the supply chain, meaning suppliers in the industry must have a good understanding of the new regulation in order to do business. Problems arise when the supplier fails to take the necessary steps to understand and implement MDR requirements. …
  • Increasing Life Sciences Manufacturing Capacity

    Supply chain disruptions have forced manufacturers and producers across the globe to reexamine how they source raw materials, inventory, produce, and disseminate what they produce. In an Australasian BioTechnology article, Facilities for a Strong Future , Emerson’s Michalle Adkins and Makarand Mujumdar share how pharmaceutical and biotech manufacturers can improve local capacity to meet the needs of the regions in which…
  • Four Pillars for Life Sciences Line and Facility Efficiency

    The overall Line and Facility effectiveness is becoming an increasing area of focus for Life Sciences manufacturers, where they are continually striving to gain the most from all of the available assets and materials. Challenges such as resource bottlenecks, impacts of variability, lack of visibility to production floor schedule changes, and off-line testing limit line and facility efficiencies are all factors that can…
  • Improving Equipment Reliability for Life Sciences Manufacturers

    Reliability of assets used in the manufacturing process is paramount for safe, efficient and effective operations. Unplanned asset failures, improper asset performance, poor maintenance planning, and untimely follow-through can cause shutdowns, under-utilized production equipment, deviations, or material/product losses. I caught up with Emerson’s Ben Arriola on how this applies to operational integrity for pharmaceutical…
  • Holistic Production Readiness Strategy is Key to Operational Success

    Initiating Good Manufacturing Practices (GMP) production operations, whether as part of facility start-up, product changeover, or following a shutdown, requires complex coordination of both logical and physical process controls. Inefficient configuration and qualification practices for automation and information management systems can lead to both start-up delays and productivity losses. A few items among the many to…